Sildenafil exposure in neonates with pulmonary hypertension after administration via a nasogastric tube

Archives of Disease in Childhood: Fetal and Neonatal Edition

Volumn 95, Issue 2, 2010, Pages

  Ahsman, Maurice J ^a   Witjes, Bregje C ^a,c   Wildschut, Enno D ^b   Sluiter, Ilona ^b   Vulto, Arnold G ^a   Tibboel, Dick ^b   Mathot, Ron A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; BOSENTAN; DESMETHYLSILDENAFIL; DIURETIC AGENT; DRUG METABOLITE; FLUCONAZOLE; INOTROPIC AGENT; SEDATIVE AGENT; SILDENAFIL; UNCLASSIFIED DRUG;

AGE DISTRIBUTION; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE TITRATION; DRUG EXPOSURE; EXTRACORPOREAL OXYGENATION; FEMALE; HUMAN; MALE; NASOGASTRIC TUBE; NEWBORN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SIMULATION;

ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BIRTH WEIGHT; CAPSULES; EXTRACORPOREAL MEMBRANE OXYGENATION; HUMANS; HYPERTENSION, PULMONARY; INFANT; INFANT, NEWBORN; INTUBATION, GASTROINTESTINAL; OFF-LABEL USE; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; SULFONES;

EID: 77949821533     PISSN: 13592998     EISSN: 14682052     Source Type: Journal    
DOI: 10.1136/adc.2009.168336     Document Type: Article

References (27)

1. Walsh-Sukys MC, Tyson JE, Wright LL, et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics 2000;105:14-20.
2. Sola A, Baquero H. [Oral sildenafil in neonatal medicine: "tested in adults also used in neonates"]. An Pediatr (Barc) 2007;66:167-76.
3. Noori S, Friedlich P, Wong P, et al. Cardiovascular effects of sildenafil in neonates and infants with congenital diaphragmatic hernia and pulmonary hypertension. Neonatology 2007;91:92-100.
4. Baquero H, Soliz A, Neira F, et al. Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study. Pediatrics 2006;117:1077-83.
5. Keller RL, Hamrick SE, Kitterman JA, et al. Treatment of rebound and chronic pulmonary hypertension with oral sildenafil in an infant with congenital diaphragmatic hernia. Pediatr Crit Care Med 2004;5:184-7.
6. Mukherjee A, Dombi T, Wittke B, et al. Population pharmacokinetics of sildenafil in term neonates: evidence of rapid maturation of metabolic clearance in the early postnatal period. Clin Pharmacol Ther 2009;85:56-63.
7. Paul GA, Gibbs JS, Boobis AR, et al. Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol 2005;60:107-12.
8. Janssen DJ, Carnielli VP, Cogo P, et al. Surfactant phosphatidylcholine metabolism in neonates with meconium aspiration syndrome. J Pediatr 2006;149:634-9.
9. Peters JW, Anderson BJ, Simons SH, et al. Morphine pharmacokinetics during venoarterial extracorporeal membrane oxygenation in neonates. Intensive Care Med 2005;31:257-63.
10. Peters JW, Anderson BJ, Simons SH, et al. Morphine metabolite pharmacokinetics during venoarterial extra corporeal membrane oxygenation in neonates. Clin Pharmacokinet 2006;45:705-14.
11. Council of Europe: Uniformity of content of single-dose preparations. In: European Pharmacopoeia. 6th edn. Strasbourg, France: Council of Europe, 2007;278.
12. Witjes BC, Ahsman MJ, van der Nagel BC, et al. Simultaneous assay of sildenafil and desmethylsildenafil in neonatal plasma by ultra-performance liquid chromatography-tandem mass spectrometry. Biomed Chromatogr 2010;24:180-5.
13. Mehrotra N, Gupta M, Kovar A, et al. The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy. Int J Impot Res 2007;19:253-64.
14. Karlsson MO, Savic RM. Diagnosing model diagnostics. Clin Pharmacol Ther 2007;82:17-20.
15. Savic RM, Karlsson MO. Shrinkage in empirical Bayes estimates for diagnostics and estimation: problems and solutions (presentation). In Proceedings of the Population Approach Group Europe. Copenhagen, Denmark, 2007.
16. Savic RM, Wilkins J, Karlsson MO. (Un)informativeness of empirical Bayes estimate-based diagnostics. American Association of Pharmaceutical Scientists, 2006.
17. Piena M, Albers MJ, Van Haard PM, et al. Introduction of enteral feeding in neonates on extracorporeal membrane oxygenation after evaluation of intestinal permeability changes. J Pediatr Surg 1998;33:30-4.
18. Gupta M, Kovar A, Meibohm B. The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction. J Clin Pharmacol 2005;45:987-1003.
19. Wernovsky G, Wypij D, Jonas RA, et al. Postoperative course and hemodynamic profile after the arterial switch operation in neonates and infants. A comparison of low-flow cardiopulmonary bypass and circulatory arrest. Circulation 1995;92:2226-35.
20. Zuppa AF, Nadkarni V, Davis L, et al. The effect of a thyroid hormone infusion on vasopressor support in critically ill children with cessation of neurologic function. Crit Care Med 2004;32:2318-22.
21. Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 2008;48:303-32.
22. Nichols DJ, Muirhead GJ, Harness JA. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol 2002;53(Suppl 1):5S-12S.
23. Buck ML. Pharmacokinetic changes during extracorporeal membrane oxygenation: implications for drug therapy of neonates. Clin Pharmacokinet 2003;42:403-17.
24. Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-57.
25. Collard HR, Anstrom KJ, Schwarz MI, et al. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest 2007;131:897-9.
26. Singh TP, Rohit M, Grover A, et al. A randomized, placebo-controlled, doubleblind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J 2006;151:851.e1-5.
27. Abman S, Jobe A, Chernick V, et al. Strategic plan for pediatric respiratory diseases research: an NHLBI working group report. Pediatr Pulmonol 2009;44:2-13.